Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. Co. is focused on developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. We show 17 historical shares outstanding datapoints in our IKT shares outstanding history coverage, used to compute IKT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IKT market cap history over the course of time is important for investors
interested in comparing IKT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IKT versus a peer is one thing; comparing
IKT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IKT can fluctuate over the course of history.
With this page we aim to empower investors researching IKT by allowing them to research the IKT market cap history. |
Free IKT Email Alerts:
Video: The Importance of Market Cap
